Loss of Epidermal HIF-1α Blocks UVB-Induced Tumorigenesis by Affecting DNA Repair Capacity and Oxidative Stress.


Journal

The Journal of investigative dermatology
ISSN: 1523-1747
Titre abrégé: J Invest Dermatol
Pays: United States
ID NLM: 0426720

Informations de publication

Date de publication:
09 2019
Historique:
received: 08 10 2018
revised: 09 01 2019
accepted: 23 01 2019
pubmed: 18 3 2019
medline: 17 6 2020
entrez: 18 3 2019
Statut: ppublish

Résumé

HIF-1α is constitutively expressed in mouse and human epidermis. It plays a crucial role in skin physiology, including the response of keratinocytes to UVR. However, little information is available about its role in photocarcinogenesis. Using a multistage model of UVB radiation-induced skin cancer, we show that the knockout of Hif-1α in the epidermis prevents tumorigenesis but at the same time triggers the formation of hyperkeratotic plaques. Our results indicate that the absence of oncogenic transformation in Hif-1α-ablated mice is related to increased DNA repair in keratinocytes, whereas the formation of hyperkeratotic plaques is caused by an increase in the levels of reactive oxygen species. Indeed, impairing the DNA repair machinery by ablating xeroderma pigmentosum C restored the UVB-induced neoplastic transformation of Hif-1α-ablated keratinocytes, whereas the development of hyperkeratotic plaques was blocked by chronic antioxidant treatment. We conclude that HIF-1α plays a procarcinogenic role in UVB-induced tumorigenesis.

Identifiants

pubmed: 30878676
pii: S0022-202X(19)31329-6
doi: 10.1016/j.jid.2019.01.035
pii:
doi:

Substances chimiques

DNA-Binding Proteins 0
Hif1a protein, mouse 0
Hypoxia-Inducible Factor 1, alpha Subunit 0
Xpc protein, mouse 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2016-2028.e7

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Walid Mahfouf (W)

University of Bordeaux, Institut National de la Santé et de la Recherche Médicale, Biothérapie des Maladies Génétiques Inflammatoires et Cancers, U1035, F-33000 Bordeaux, France.

Mohsen Hosseini (M)

University of Bordeaux, Institut National de la Santé et de la Recherche Médicale, Biothérapie des Maladies Génétiques Inflammatoires et Cancers, U1035, F-33000 Bordeaux, France.

Elodie Muzotte (E)

University of Bordeaux, Institut National de la Santé et de la Recherche Médicale, Biothérapie des Maladies Génétiques Inflammatoires et Cancers, U1035, F-33000 Bordeaux, France.

Martin Serrano-Sanchez (M)

University of Bordeaux, Institut National de la Santé et de la Recherche Médicale, Biothérapie des Maladies Génétiques Inflammatoires et Cancers, U1035, F-33000 Bordeaux, France.

Lea Dousset (L)

University of Bordeaux, Institut National de la Santé et de la Recherche Médicale, Biothérapie des Maladies Génétiques Inflammatoires et Cancers, U1035, F-33000 Bordeaux, France.

François Moisan (F)

University of Bordeaux, Institut National de la Santé et de la Recherche Médicale, Biothérapie des Maladies Génétiques Inflammatoires et Cancers, U1035, F-33000 Bordeaux, France.

Walid Rachidi (W)

Nucleic Acids Lesions Laboratory, Service de Chimie Inorganique et Biologique/Institut Nanosciences et Cryogénie, Commissariat à l'Énergie Atomique et aux Énergies Alternatives, Université Joseph Fourier, Grenoble, France.

Alain Taieb (A)

University of Bordeaux, Institut National de la Santé et de la Recherche Médicale, Biothérapie des Maladies Génétiques Inflammatoires et Cancers, U1035, F-33000 Bordeaux, France; Centre de Référence pour les Maladies Rares de la Peau, Centre Hospitalier Universitaire de Bordeaux, France; Département de Dermatologie & Dermatologie Pédiatrique, Centre Hospitalier Universitaire de Bordeaux, France.

Jana Rudolf (J)

University of Bordeaux, Institut National de la Santé et de la Recherche Médicale, Biothérapie des Maladies Génétiques Inflammatoires et Cancers, U1035, F-33000 Bordeaux, France.

Hamid Reza Rezvani (HR)

University of Bordeaux, Institut National de la Santé et de la Recherche Médicale, Biothérapie des Maladies Génétiques Inflammatoires et Cancers, U1035, F-33000 Bordeaux, France; Centre de Référence pour les Maladies Rares de la Peau, Centre Hospitalier Universitaire de Bordeaux, France. Electronic address: hamid-reza.rezvani@u-bordeaux.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH